Molecular mass: 1,321.412 g/mol PubChem compound: 3000502
Capreomycin is indicated for:
Population group: only adults (18 years old or older)
Capreomycin is active against human strains of Mycobacterium tuberculosis. Frequent cross-resistance occurs between capreomycin and viomycin. Varying degrees of cross-resistance between capreomycin and kanamycin and neomycin have been reported. No cross-resistance has been observed between capreomycin and isoniazid, aminosalicylic acid, cycloserine, streptomycin, ethionamide or ethambutol. Capreomycin should be used concomitantly with other appropriate antituberculous agents for the treatment of pulmonary infections caused by capreomycin- susceptible strains of Mycobacterium tuberculosis when the primary agents (isoniazid, rifampicin, streptomycinand ethambutol) have been ineffective or cannot be used because of toxicity or the presence of resistant tubercle bacilli. 1
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Capreomycin is contraindicated in the following cases:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
